Announcements Trials

Browse Landscape

Phase

Status

Unknown 1 Recruiting 1 Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma, Mantle-Cell 2 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma, Follicular 1 Lymphoma 1

Interventions

Rituximab 3 Cyclophosphamide 3 obinutuzumab 2 fludarabine 2 daratumumab 2 Specimen Handling 2 Prednisone 2 Magnetic Resonance Spectroscopy 2 Immunotherapy, Adoptive 2 Dexamethasone 2 Bortezomib 2 Biopsy 2 Bendamustine Hydrochloride 2 zanubrutinib 1 venetoclax 1 tafasitamab 1 selinexor 1 prednylidene 1 polatuzumab vedotin 1 pegaspargase 1 orelabrutinib 1 nelarabine 1 merphos 1 glofitamab 1 exifone 1 dexamethasone acetate 1 dexamethasone 21-phosphate 1 deltacortene 1 calaspargase pegol 1 auricularum 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Not yet recruiting × Lymphoma × orelabrutinib × Clear all

NCT07206264 2025-10-03

ADAPT-MCL

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Not yet recruiting

Lymphoma, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡